Methods for treatment of fibrotic diseases
Methods for treatment of fibrotic diseases using compounds of formula I wherein R A is hydrogen, R 7 and R 8 are independently selected from H and SO 2 NR 3 R 4 , one of R 7 and R 8 is hydrogen, and R 1 , R 2 , R 3 , and R 4 are each independently selected from H, alkyl, heteroalkyl, cycloalkyl, arylcycloalkyl, aryl, heteroaryl, heterocycloalkyl, and each of NR 1 R 2 and NR 3 R 4 can independently combine to form a heterocycloalkyl, and wherein said alkyl, heteroalkyl, cycloalkyl, arylcycloalkyl, aryl, heteroaryl, or heterocycloalkyl may be optionally substituted, or a pharmaceutically acceptable salt, ester, amide, stereoisomer, geometric isomer or prodrug thereof.
1. A method of treating pulmonary fibrosis in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula:
or a pharmaceutically acceptable salt thereof, wherein said method prevents beta-catenin from association with trans-ducin-beta-like 1 (TBL1) protein in the patient, wherein the therapeutically effective dose is from about 0.0001 to about 1000 mg/kg/day.
2. The method of claim 1 , wherein said administering is done through one or more of intravenous, parenteral, oral, inhalation (including aerosolized delivery), buccal, intranasal, rectal, intra-lesional intraperitoneal, intradermal, transdermal, subcutaneous, intra-arterial, intracardiac, intraventricular, intracranial, intratracheal, intrathecal administration, intramuscular injection, intravitreous injection, and topical application methods.
3. The method of claim 1 wherein said administering is done through aerosolized delivery.
4. The method of claim 1 wherein said administering is done through intratracheal delivery.
5. The method of claim 3 , wherein said compound is formulated in a solution comprising a poloxamer and sorbitol.
6. The method of claim 3 , wherein said compound is formulated in a nano-milled suspension.